Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$108.18 USD

108.18
1,175,736

-0.51 (-0.47%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $108.25 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher (TMO) Announces the Acquisition of CorEvitas

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of CorEvitas is likely to strengthen its value proposition.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout

by Zacks Equity Research

ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.

Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.

Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover

by Zacks Equity Research

If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) due to the continued procedure recovery and the strength of emerging markets.

Ensign Group (ENSG) Up 26% in a Year: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.

Envista (NVST) Gains From New Acquisitions Amid FX Woes

by Zacks Equity Research

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.

John Blank headshot

Where Might 2024 Investors Harvest Returns?

by John Blank

One source for those answers: Chief Investment Officers (CIOs).

Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee

by Zacks Equity Research

Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.

Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches

by Zacks Equity Research

Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.

Why You Should Retain Walgreens Boots (WBA) Stock for Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.

Here's Why Investors Should Retain Phibro (PAHC) for Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).

Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?

by Zacks Equity Research

Zimmer (ZBH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Here's Why You Should Retain Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.

John Blank headshot

The FOMC, ECB, and BoJ: Global Week Ahead

by John Blank

Key risk market moments in the Global Week Ahead? They center on major central banks, with the U.S. Fed, the European Central Bank (ECB) and the Bank of Japan (BoJ) meeting.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

by Zacks Equity Research

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

LabCorp (LH) Provides Update on Planned Spinoff of Fortrea

by Zacks Equity Research

After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.